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The protein kinase C (PKC) family of genes encode serine/threonine kinases that regulate proliferation, apoptosis, cell survival and
migration. Multiple isoforms of PKC have been described, one of which is PKCd. Currently, it is unclear whether PKCd is involved in
promoting or inhibiting cancer formation/progression. The aim of this study was therefore to investigate the expression of PKCd in
human breast cancer and relate its levels to multiple parameters of tumour progression. Protein kinase Cd expression at the mRNA
level was measured using real-time PCR (n¼208) and at protein level by both immunoblotting (n¼94) and ELISA (n¼98).
Following immunoblotting, two proteins were identified, migrating with molecular masses of 78 and 160kDa. The 78kDa protein is
likely to be the mature form of PKCd but the identity of the 160kDa form is unknown. Levels of both these proteins correlated
weakly but significantly with PKCd concentrations determined by ELISA (for the 78kDa form, r¼0.444, Po0.005, n¼91 and for the
160kDa form, r¼0.237, P¼0.023, n¼91) and with PKCd mRNA levels (for the 78kDa form, r¼0.351, P¼0.001, n¼94 and for
the 160kDa form, r¼0.216, P¼0.037, n¼94). Protein kinase Cd mRNA expression was significantly higher in oestrogen receptor
(ER)-positive compared with ER-negative tumours (P¼0.007, Mann–Whitney U-test). Increasing concentrations of PKCd mRNA
were associated with reduced overall patient survival (P¼0.004). Our results are consistent with a role for PKCd in breast cancer
progression.
British Journal of Cancer (2008) 99, 1644–1650. doi:10.1038/sj.bjc.6604728 www.bjcancer.com
Published online 28 October 2008
& 2008 Cancer Research UK
Keywords: breast cancer; protein kinase Cd
                                                         
The protein kinase C (PKC) family of genes encode serine/
threonine kinases that regulate proliferation, apoptosis, cell
survival and migration (for review, see Jackson and Foster, 2004;
Griner and Kazanietz, 2007). Currently, nine PKC genes are known
to exist. The PKC isoforms are classified into three subfamilies
based on their structural and enzymatic properties: classical PKCs
(a, b1, b2 and g) are activated by diacylglycerol (DAG) and
calcium, novel PKCs (d, e, Z and y) are activated by DAG but are
calcium-insensitive and atypical PKCs (z and l/i) respond to
neither DAG nor calcium. Although, originally, PKCs were
believed to be mostly promitotic (Griner and Kazanietz, 2007),
more recent findings suggest that the effects of at least some PKCs
may be isoenzyme and cell-type dependent (Jackson and Foster,
2004; Griner and Kazanietz, 2007).
One of the PKCs shown to exhibit enigmatic properties is PKCd
(Jackson and Foster, 2004). Depending on the model system
investigated, PKCd has been shown to act as either a positive or a
negative regulator of tumour progression (Jackson and Foster,
2004). In most situations, however, PKCd has been shown to be
growth inhibitory or proapoptotic (Griner and Kazanietz, 2007). In
these situations, PKCd might be regarded as a tumour suppressor
gene.
In one of the first studies on breast cancer, Kiley et al (1999)
showed that PKCd was involved in metastasis in a rat model. More
recently, Martens et al (2005) reported that hypermethylation of
the PKCd gene in oestrogen receptor (ER)-positive breast cancer
patients was associated with a favourable response to hormone
therapy in patients with advanced breast cancer, whereas Assender
et al (2007) found that elevated PKCd protein was associated with
endocrine sensitivity. In breast cell lines, on the other hand,
tamoxifen-resistant subclones tend to have higher PKCd protein
expression than their parental tamoxifen-sensitive counterparts
(Nabha et al, 2005; Assender et al, 2007).
The aim of this study was to carry out a more detailed study on
PKCd in human breast cancer, in particular to relate PKCd
expression to multiple parameters of tumour progression. Our
results show that increased PKCd expression is associated with
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spoor outcome. This finding is consistent with a role for PKCd in
breast cancer progression.
MATERIALS AND METHODS
Selection of patients and patient treatment
The breast cancers investigated in this study were random samples
submitted for routine histopathology at St Vincent’s University
Hospital, Dublin. The piece of tumour used for experimental
purposes was dissected out by a histopathologist, snap-frozen
in liquid nitrogen and stored at  801C until use. Tissue samples
were homogenised using a Mikro-Dismembrator (Braun Biotech
T1 International, Melsungen, Germany). Table 1 summarises
the characteristics of the breast carcinomas analysed. Samples
were obtained with institutional board approval from St Vincent’s
University Hospital.
For relating PKCd to patient outcome, both disease-free and
overall survival were used as end points. Disease-free interval
was defined as the time from date of initial diagnosis to the
date of first recurrence/metastasis. Overall survival was defined as
the time from initial diagnosis to death from any cause or date of
last follow-up. The median patient follow-up period was 34.8
months (0–137). Thirty-nine patients (18.8%) received adjuvant
polychemotherapy, 50 (24%) received monohormone therapy and
107 (51.4) received combined chemotherapy and hormonal
therapy. Two patients were not given any adjuvant systemic
therapy, whereas for 10 patients, the adjuvant treatment was
unknown.
RNA isolation and real-time PCR
RNA was extracted from tumour samples using a commercially
available column-based method (RNeasy
s Mini kit; Qiagen,
Hilden, Germany) and cDNA synthesised using Superscript II
(Invitrogen, Carlsbad, CA, USA). The quality and quantity of the
RNA was assessed using gel electrophoresis and spectrophotom-
etery. RNA was DNase I treated (DNase I; NEB, Ipswich, MA, USA)
before reverse transcription and cDNA was subsequently treated
with RNAse H (NEB).
The expression of three housekeeping genes, that is, porphobi-
linogen deaminase (PBGD), hypoxanthine-guanine phosphoribo-
syltransferase (HPRT) and b-actin as well as PKCd was measured
using SYBR green-based real-time PCR (Roche LightCycler 2.0;
Roche Diagnostics GmbH, Mannheim, Germany). The primer
sequences for PKCd were sense, TTCGGGAAGGTGCTGCTTG
and antisense, TGCCCTTGCTGTGTAGAAAC, whereas those for
b-actin were sense, GCACAGAGCCTCGCCTTTG and antisense
CGCCCACATAGGAATCCTTC. The primer sequences for PBGD
and HPRT were as previously described by Sieuwerts et al (2005).
Each reaction mixture contained 20ng of cDNA and a concentra-
tion of 0.33mM of each primer in a final volume of 20ml with
Quantitect
s SYBR green reaction master mix (Qiagen and Roche
Diagnostics GmbH). The optimised amplification protocol con-
sisted of an initial denaturation step of 951C for 15min, followed
by 40 amplification cycles at 951C for 15s, annealing at 601C for
30s and elongation at 721C for 25s. A constant temperature ramp
of 201Cs
 1 was used throughout each of the steps. Measurements
of fluorescence were taken at the end of each cycle. The PCR
products were melted by increasing the temperature from 60 to
951C (0.11Cs
 1). Finally, the samples and carousel were cooled to
401C. Positive and negative controls were included in each
run. The negative control lacked template, whereas the positive
control was pooled RNA extracted from HeLa cells. Levels of
the PKCd gene, expressed relative to the housekeeping set
(HPRT, PBGD and b-actin), were quantified as follows: mRNA
target¼Eðmean Ct housekeeping mean Ct targetÞ (Sieuwerts et al, 2005).
Immunisation
For PKCd, two different 16-mer peptides (peptide PKCD2
(296–311) and peptide PKCD3 (314–329)), both located in the
flexible linker region between the N-terminal regulatory and the
C-terminal protein kinase domain, were synthesised (Pineda,
Berlin, Germany), conjugated to KLH, and used for immunisations
in chicken and rabbit. Immunisations were performed according
to a time schedule with boosting intervals of 2 weeks. Chickens
were immunised intramuscularly (pectoral muscle) with 120mgo f
conjugated peptide PKCD2. Eggs from the immunised chickens
were collected daily and stored at 41C.
Antibodies were isolated from egg yolk using a standard
procedure of step precipitation of proteins by applying increasing
concentrations of polyethyleneglycol (PEG precipitation) as
described earlier (Grebenchtchikov et al, 2002). This procedure
yielded IgY fractions (avian analogue of IgG) with a protein purity
of approximately 95% (SDS–PAGE). The first injection (Freund’s
complete adjuvant) (PKCD3) in rabbit was in the popliteal gland,
whereas booster injections (Freund’s incomplete adjuvant) were
administered subcutaneously with 2 weeks interval. In total, 10
booster injections were administered. Blood from rabbits was
collected just before the inoculations in citrate tubes. After
centrifugation, the citrate plasmas were stored at  201C.
For immunoblotting, unpurified rabbit anti-PKCD3 polyclonal
antibodies (V35) were used, whereas for ELISA chicken, anti-
PKCD2 and rabbit anti-PKCD3 antibodies were affinity purified
(Grebenschikov et al, 1997). Polyclonal antibodies were eluted
from the columns with Gly/HCl buffer (pH 2.40), followed by
immediate neutralisation to pH 7.5. Purified antibodies were
Table 1 Pathological features and ER status of the breast carcinomas
used
Tumour
characteristics
PCR
n (%)
Western blot
n (%)
ELISA
n (%)
Size (cm)
p2 53 (25.5) 20 (21.3) 20 (20.4)
42–5 127 (61.1) 62 (66.0) 62 (63.2)
45 15 (7.2) 8 (8.5) 8 (8.2)
Unknown 13 (6.2) 4 (4.2) 8 (8.2)
Grade
1 and 2 98 (47.1) 38 (40.4) 38 (38.8)
3 100 (48.1) 54 (57.5) 57 (58.2)
Unknown 10 (4.8) 2 (2.1) 3 (3.0)
Nodal status
Negative 87 (41.8) 43 (45.7) 41 (41.8)
Positive 109 (52.4) 48 (51.1) 53 (54.1)
Unknown 12 (5.8) 3 (3.2) 4 (4.1)
ER
Negative 51 (24.5) 24 (25.5) 24 (24.5)
Positive 151 (72.6) 69 (73.4) 73 (74.5)
Unknown 6 (2.9) 1 (1.1) 1 (1.0)
Age
p50 65 (31.2) 24 (25.5) 28 (28.6)
450 143 (68.8) 70 (74.5) 70 (71.4)
Histological type
Ductal 173 (83.2) 83 (88.3) 86 (87.8)
Lobular 19 (9.1) 6 (6.4) 7 (7.1)
Ductal and lobular 11 (5.3) 3 (3.2) 3 (3.1)
Unknown 5 (2.4) 2 (2.1) 2 (2.0)
ER¼oestrogen receptor.
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scharacterised using ‘one-side ELISA’ methodology in which
peptide fragments were coupled to the microtitre well. Specificity
of the antibodies was verified by western blot analysis, which
demonstrated a strong reaction with recombinant full-length PKCd
and truncated PKCd, encompassing the N-terminal regulatory
domain, but no reaction with the closely related recombinant
PKCg.
Protein isolation and immunoblot analysis
Protein was extracted from tissue samples using 50mmoll
 1
Tris-HCl (pH 7.4) containing protease inhibitor cocktail (Roche
Diagnostics GmbH) and Triton X-100 (1%) under agitation at 41C
for 1h. A bicinchoninic acid assay (Pierce, Rockford, IL, USA) was
used to determine total protein concentration. Equal amounts
of protein were separated on SDS–PAGE and transferred to
nitrocellulose membranes (Sigma, St Louis, MO, USA). Mem-
branes were blocked in 5% low-fat dry milk (Marvel instant-dried
skimmed milk) in TBS-T for 1h at room temperature and then
stained overnight with mouse anti-PKCd monoclonal antibody
(0.25mgml
 1; BD Biosciences Pharmingen, San Diego, CA, USA
(catalogue no. 610397)). Following three washes for 10min in
TBS-T, the membrane was incubated with 1:1000 horseradish
peroxidase-conjugated anti-mouse secondary antibody (Sigma)
for 1h at room temperature before incubation with 6ml of
chemiluminescence reagent (Luminol; Santa Cruz Biotechnology,
Santa Q7 Cruz, CA, USA) for 1min. Membranes were exposed to
X-ray film (Fujifilm) in the dark for 15min. Positivity of
expression was determined based on the presence of a visible
band. The intensity of the protein bands observed was semi-
quantified using the UVIBandMap programme (Windows applica-
tion VIO.02), with normalisation of PKCd protein against b-actin.
Specificity of the antibody reaction was confirmed by (a) detection
of the human recombinant PKCd protein (Abcam, Cambridge, UK)
at 78kDa, which was used as a positive control, (b) omission of the
primary antibody and (c) detection of a similar pattern of
expression using a second primary antibody against PKCd (see
above for preparation of this antibody).
ELISA
Protein kinase Cd concentrations were measured by ELISA with
the same experimental setup as described earlier (Grebenschikov
et al, 1997). The assay format incorporated four different
antibodies: (a) duck anti-chicken IgY antibody, (b) chicken anti-
PKCD2 antibody, (c) rabbit anti-PKCD3 and (d) goat anti-rabbit
antibody labelled with HRP. The procedure started by treating the
microtitre plates with coating antibody (duck anti-chicken IgY,
overnight at 41C), followed by blocking with BSA (2h at 371C) and
incubation with capture antibody (chicken anti-PKCD2) for 2h at
371C. Incubation with the cancer extracts, reference sample and
the standards was overnight at 41C. For calibration, recombinant
PKCd preparation provided by Cell Sciences (Canton, MA, USA)
was used. Incubation with trapping antibody (rabbit anti-PKCD3)
as well as the subsequent incubation with detection antibody (goat
anti-rabbit labelled with HRP) was performed for 2h at ambient
temperature. The incubation with OPD substrate solution was
performed in darkness for 30min at ambient temperature. The
reaction was stopped by the addition of H2S04 and the optical
density was measured at 492nm within 30min. The analytical
sensitivity, defined as the amount of PKCd giving a signal in the
ELISA greater than two standard deviations above blank values,
was 0.5ngml
 1. For estimation of the accuracy, a cytosolic
reference preparation (labelled preparation 311000) was used.
The mean PKCd concentration in preparation 311000 was
28.4ngml
 1, whereas the within-run coefficient of variation (CV)
and the between-run CV were 3.1% (n¼8) and 4.1% (n¼7),
respectively.
Statistics
The Spearman rank correlation was used to compare continuous
variables. The Mann–Whitney U-test, Kruskal–Wallis test (for
continuous/nominal variables) and w
2 test (for nominal data) were
used to determine relationships between the various variables.
Computations were carried out using SPSS v.11 (SPSS Inc.
Headquarters, Chicago, IL, USA). A two-sided Po0.05 was
considered statistically significant. Protein kinase Cd mRNA was
related to patient outcome using the Cox regression model. For
this analysis, PKCd mRNA level was treated as a continuous
variable.
RESULTS
Protein kinase Cd expression in breast carcinomas
Protein kinase Cd mRNA was measured by real-time PCR in 208
breast carcinoma samples (see Table 1 for clinical characteristics of
the cohort). The median value relative to the housekeeping gene
set was 1.97-fold with a range from undetectable to 17.3-fold.
Ninety-four representative samples of the 208 analysed by RT–
PCR were subjected to immunoblotting for PKCd (see also Table 1
for clinical characteristics of this subgroup). Figure 1A illustrates a
representative immunoblot of PKCd protein expression, following
electrophoresis under reducing conditions. Using a mouse anti-
PKCd monoclonal antibody (BD Biosciences Pharmingen), two
bands were identified, migrating with molecular masses of B160
and 78kDa. On the basis of its known molecular mass, the 78kDa
band was regarded as the parent form of PKCd (Emoto et al, 1995).
To our knowledge, a 160kDa form of PKCd has not been
previously described. Thus, the identity of this band is unknown.
The 78kDa protein was found in 72 out of 94 (76.6%) of the
samples. Concentrations ranged from undetectable to 1.97
arbitrary units, the median value being 0.072 arbitrary units. On
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Figure 1 (A) Representative immunoblot of PKCd expression in five primary breast carcinoma samples (S1–S5). Loading control, b-actin. (B and C)
Confirmation of antibody specificity. Protein kinase Cd expression was examined in two primary breast carcinoma samples S1 and S2 using the mouse anti-
PKCd monoclonal antibody (BD Biosciences) (B) and the rabbit anti-PKCD3 polyclonal antibody (V35) (C). The same carcinoma samples were used in (B)
and (C). Positive control, human recombinant PKCd protein (þC).
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sthe other hand, the 160kDa protein was detected in 86 out of 94
(91.5%) of the samples with concentrations ranging from 0 to 5.15
arbitrary units and a median value of 0.205 arbitrary units.
As a 160kDa form of PKCd had not previously been described,
we decided to check its reactivity with a second antibody against
PKCd. Using a rabbit polyclonal antibody directed against peptide
PKCD3, encompassing amino acids 314–329 of PKCd (for details,
see Materials and Methods), the 160kDa band was also detected
(Figure 1B and C), suggesting that this band may be either a new
form of PKCd, PKCd complexed to an unknown protein or a
protein closely related to PKCd. To check the possibility that the
160kDa band might be a dimer of the parental form of PKCd,w e
increased the concentration of the reducing agent, that is b-
mercaptoethanol, in the loading buffer from 5 to 20%. The pattern
of expression for both the 78kDa parent form and the 160kDa
forms was not altered, suggesting that the 160kDa protein is
unlikely to be a dimer.
Using the Spearman rank correlation test (Figure 2A), a weak
but significant correlation was found between the 78kDa parent
form of PKCd and the 160kDa protein in the carcinomas
(r¼0.302, r
2¼0.081, P¼0.003, n¼94). Of the 94 samples
investigated, 70 (74.5%) were positive for both proteins, whereas
six (6.4%) were negative for both forms. Two samples (2.1%)
expressed the 78kDa form in the absence of the 160kDa form.
Sixteen of the samples (17%) expressed the 160kDa form in the
absence of the 78kDa band.
Extracts from 98 samples of the 208 analysed by RT–PCR were
assayed for PKCd by ELISA. Using ELISA, the total PKCd protein
concentration ranged from undetectable to 176.0ng per mg
protein, with the median value being 10.5ng per mg protein. A
significant but weak correlation was found between the levels of
PKCd as determined by ELISA and both the 78kDa form of PKCd
and the 160kDa protein determined by immunoblotting (for the
78kDa form, r¼0.444, r
2¼0.187, Po0.005, n¼91 and for the
160kDa form, r¼0.237, r
2¼0.046, P¼0.023, n¼91; Figure 2B
and C).
As shown in Figure 2D and E, a significant but weak correlation
was found between PKCd mRNA expression and both the 78kDa
PKCd protein and the 160kDa band (for the 78kDa form,
r¼0.351, r
2¼0.114, P¼0.001, n¼94 and for the 160kDa band,
r¼0.216, r
2¼0.036, P¼0.037, n¼94). Protein kinase Cd mRNA
expression also correlated with PKCd protein, as determined by
ELISA (r¼0.350, r
2¼0.113, Po0.005, n¼98; Figure 2F).
Relationship between PKCd expression and both tumour
characteristics and patient outcome
Protein kinase Cd mRNA and protein levels were related to
established prognostic factors for breast cancer, that is tumour
size, presence or absence of axillary node metastasis, tumour
grade, histology type, ER status and patient age at time of
diagnosis (Table 2). No significant correlation was found between
PKCd expression and tumour size, and the presence or absence of
axillary node metastasis or histology type. Levels of PKCd mRNA,
however, were significantly higher in ER-positive tumours
compared with ER-negative tumours (Mann–Whitney U-test:
P¼0.007, n¼202; Figure 3A) and in patients older than 50 years
at diagnosis than in those younger than 50 years (Mann–Whitney
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Figure 2 (A) Bivariate scattergram illustrating the relationship between the 78kDa parent form of PKCd and the 160kDa form. (B and C) Relationship
between PKCd protein as measured by both ELISA and immunoblot. Bivariate scattergrams illustrating the positive correlations between PKCd protein levels
as measured by ELISA and (B) the 78kDa PKCd form, (C) the 160kDa form. (D and E) Relationship between PKCd mRNA and PKCd protein as measured
by real-time PCR and immunoblotting. Bivariate scattergrams illustrating the positive correlations between PKCd mRNA and (D) the 78kDa PKCd;( E) the
160kDa form. (F) Bivariate scattergram illustrating the positive correlation between PKCd mRNA and total PKCd protein as measured by ELISA. Scale on
both axes is logarithmic. Analysis performed using the Spearman rank statistical test.
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sU-test: P¼0.029, n¼208; Figure 3B). Levels of the 78kDa form of
PKCd, but not the 160kDa protein, were significantly elevated in
high-grade tumours compared with low-grade tumours (Mann–
Whitney U-test: P¼0.016, n¼92; Figure 3C). Levels of the 160kDa
protein, but not the 78kDa protein, were significantly elevated in
ER-positive tumours compared with ER-negative tumours
(Mann–Whitney U-test: P¼0.030, n¼93; Figure 3D).
Protein kinase Cd mRNA expression was related to both patient
disease-free interval and overall survival. Although increasing
levels of PKCd, treated as a continuous variable, tended to
correlate with shorter disease-free interval, this relationship failed
to reach statistical significance (P¼0.074) (Table 3). However, the
increasing expression of PKCd was associated with a significantly
shorter overall survival (P¼0.004) (Table 3). Other factors
associated with shortened survival included tumour size (treated
as a continuous variable) (P¼0.015), tumour grade (grade 3 vs
grades 1 and 2 combined) (P¼0.009) and the number of lymph
nodes with metastasis (P¼0.002). Using multivariate analysis,
PKCd mRNA predicted overall survival, independent of the
traditional prognostic factors (Table 3). Protein kinase Cd protein
levels were not related to patient outcome as the number of
samples analysed at the protein level was too low and we did not
have enough events (i.e., recurrences or deaths) to provide reliable
associations with outcome.
DISCUSSION
This is one of the most comprehensive studies published to date on
PKCd in a large cohort of human breast cancers. Our results show
that this gene is variably expressed at both the mRNA and protein
levels in breast cancer and that PKCd protein levels in breast cancer
specimens, as measured by immunoblotting and ELISA, correlate
weakly but significantly with each other and with PKCd mRNA
levels. At both mRNA and protein levels, the expression of PKCd was
independent of tumour size, lymph node status and histology type.
Levels of PKCd mRNA were, however, significantly higher in ER-
positive compared with ER-negative patients. This finding suggests a
possible relationship between PKCd expression and endocrine
sensitivity in patients with breast cancer. In this context, it is of
interest to note that Martens et al (2005) found that hypermethyla-
tion of the PKCd gene in ER-positive patients was associated with a
favourable response to tamoxifen therapy in advanced breast cancer.
Although the effect of hypermethylation on the expression of PKCd
mRNA was not investigated in that study, gene hypermethylation is
generally, but not universally, associated with a decreased expres-
sion (Branscombe and Jones, 2007). While this work was in
progress, Assender et al (2007) reported that elevated PKCd protein,
as determined by immunohistochemistry, was associated with
endocrine sensitivity in patients with advanced breast cancer.
As only a minority of the patients in this study were treated with
hormone monotherapy, it was not possible to investigate the
relationship between PKCd expression and outcome following
such a treatment. Rather, we found that elevated expression of
PKCd was associated with poor overall survival. As most of our
patients receive systemic adjuvant therapy, it was not possible to
conclude whether PKCd was prognostic, predictive or both. In any
event, our finding of a significant relationship between increased
PKCd expression and shortened overall survival is consistent with
previous studies from a model system, implicating this kinase in
breast cancer metastasis (Kiley et al, 1999).
The association between high expression of PKCd and shortened
overall survival may appear to be inconsistent with our finding of a
positive relationship between the kinase and ER (see above). This
is because ER-positive breast cancer patients are generally
regarded to have a better prognosis than ER-negative patients
(Duffy, 2006). The favourable prognostic impact of ER, however,
depends on the adjuvant therapy administered. Thus, in a study on
Table 2 Relationship between PKCd expression and characteristics of the breast carcinomas
mRNA (PCR) Protein (western blot) Protein (ELISA)
78kDa isoform 160kDa isoform
Tumour characteristics n Median P-value n Median P-value Median P-value n Median P-value
Size (cm)
p2 53 1.75 0.406* 20 0.0288 0.139* 0.2155 0.989* 20 10.56 0.635*
42–5 127 2.04 62 0.0896 0.2051 62 12.49
45 15 1.43 8 0.0367 0.2576 8 8.48
Grade
1 and 2 98 2.13 0.613 38 0.0315 0.016 0.2024 0.883 38 7.88 0.243
3 100 1.8 54 0.1003 0.1968 57 12.80
Nodal status
Negative 87 1.98 0.874 43 0.0991 0.401 0.1555 0.290 41 11.68 0.580
Positive 109 1.89 48 0.0663 0.2981 53 9.57
ER
Negative 51 1.34 0.007 24 0.0836 0.349 0.1369 0.030 24 14.30 0.977
Positive 151 2.28 69 0.0626 0.3236 73 9.57
Age
p50 65 1.97 0.029 24 0.0744 0.767 0.2335 0.900 28 7.82 0.392
450 143 2.54 70 0.0685 0.2 70 11.45
Histological type
Ductal 173 1.88 0.250* 83 0.0742 0.889* 0.2104 0.891* 86 9.71 0.336*
Lobular 19 2.15 6 0.1447 0.0917 7 20.87
Ductal and lobular 11 2.89 3 0.062 0.1792 3 26.88
ER¼oestrogen receptor; PKC¼protein kinase C. P-values were determined by either the Mann–Whitney U-test or Kruskall–Wallis test*.
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s2562 patients, ER was of prognostic value only in the subgroup
treated with adjuvant tamoxifen therapy (Khoshnoud et al, 2008).
In our study, only 24% of the patients received hormone
monotherapy, whereas most received combined hormone and
chemotherapy. Indeed, ER was not a significant predictor of
patient outcome in our group of patients.
Our finding of a significant relationship between PKCd and
overall survival, but not between the kinase and disease-free
interval, may relate to the fact that almost all our patients received
some form of systemic adjuvant therapy. A potential adverse
prognostic impact of PKCd could thus be neutralised or partially
neutralised by this adjuvant treatment. It should also be added that
while the association between PKCd and disease-free interval did
not reach statistical significance, there was a trend towards
significance, that is the P-values were 0.074 and 0.052 using
univariate and multivariate analyses, respectively.
Following immunoblotting with two different antibodies against
PKCd, we identified two main proteins, migrating with molecular
masses of 78 and 160kDa. On the basis of its known molecular
mass, the 78kDa band was taken to represent the mature form of
PKCd. To our knowledge, a 160kDa form of PKCd has not
previously been described. Further work is therefore required to
establish whether it is a new form of PKCd, a protein related to
PKCd, a complex of PKCd with an unknown protein or indeed a
non-specific band.
The 78kDa form of PKCd was expressed at higher levels in high-
grade (that is, grade 3) compared with low-grade (that is, grade 1
and 2) tumours. Grade is a well-established prognostic factor for
breast cancer with increasing grade generally being associated with
poorer outcome (Soerjomataram et al, 2008). The finding of a
positive relationship between levels of the 78kDa form of PKCd
and grade is consistent with our finding that elevated expression of
PKCd mRNA was associated with poor outcome.
As mentioned in the introduction, there is considerable
debate at present as to whether PKCd is involved in promoting
or inhibiting cancer progression. Our finding here of an
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Figure 3 Box plot representing the relationship between (A) PKCd mRNA levels and ER status in primary breast carcinomas; (B) PKCd mRNA levels and
patient age at the time of diagnosis; (C) the 78kDa PKCd protein form as measured by immunoblot and tumour grade and (D) the 160kDa form as
measured by immunoblot and ER status in primary breast carcinomas. Boxes, 25th and 75th percentiles with the median indicated; bars, 10th and 90th
percentiles. Analysis was performed using the Mann–Whitney U-test.
Table 3 Relationship between PKCd mRNA and both overall survival
and disease-free interval in breast cancer
Univariate
analysis
Multivariate analysis
Factors P-value P-value RR 95% CI
Overall survival
Tumour size (continuous) 0.015 0.172 1.206 0.922–1.578
Nodal category
a 0.002 0.037 1.996 1.044–3.816
Tumour grade (3 vs 1 and 2) 0.009 0.079 2.796 0.887–8.821
ER status 0.615 NS
b
PKCd (continuous) 0.004 0.038 1.157 1.008–1.328
Disease-free interval
Tumour size (continuous) 0.161 NS
b
Nodal category
a 0.001 0.021 1.871 1.098–3.189
Tumour grade (3 vs 1 and 2) 0.010 0.074 2.370 0.919–6.110
ER status 0.977 NS
b
PKCd (continuous) 0.074 0.052 1.125 0.999–1.268
CI¼confidence interval; PKC¼protein kinase C; RR¼relative risk.
aNodal status
divided into categories: 0, 1–3 and 43 involved nodes.
bNS, not significant
(P40.05).
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and poor outcome suggests a role for PKCd in tumour pro-
gression, at least in human breast cancer. Further studies,
ideally using prospective randomised trials, are required to
establish whether PKCd has prognostic or predictive roles in
breast cancer.
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